Dr Allan Wailoo BSc, MA, MSc, PhD

Reader in Health Economics

HEDS, ScHARR
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA
UK

Office:

Tel:(+44) (0)114 222 0729
Fax:(+44) (0)114 272 4095

E-mail: a.j.wailoo@sheffield.ac.uk

Biography

I joined ScHARR in 2000 having previously worked at the University of Leicester. I am currently a Reader in Health Economics, Director of the NICE Decision Support Unit, and a member of the Research Design Service for Yorkshire and the Humber. I have Masters and PhD degrees in Economics and recently completed a Masters in Probability and Statistics at Sheffield

Research interests

• Economic evaluation including alongside clinical trials and decision modelling
• Analysis of patient level data, particularly around health utilities
• Social values and decision making, including equity and procedural preferences

Teaching interests

I lead the "Health Economics" module for the MSc Health Economics and Decision Modelling and teach on various other modules of the same course.

I am a supervisor to the following PhD students; Chris Skedgel, Koonal Shah, Armando Vargas-Palacios. I am interested in supervising research students in a broad range of topics around economic evaluation, but particularly in relation to statistical methods and decision modelling.

Professional activities

• Director of the NICE Decision Support Unit
• Member of the NICE Medical Technologies Appraisal Committee (MTAC)
• Sub Panel Member of the NIHR Programme Grants for Applied Research
• Acting deputy director of Yorkshire and Humber Research Design Service (RDS)

Key publications

• Hernandez M, Wailoo AJ, Ara, R. (2012) Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Health State Utility Values. Value in Health available here
• Wailoo AJ, Hernandez M, Goodacre S, Sampson et al. (2010) Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction in the UK NHS: an economic analysis of the National Infarct Angioplasty Project Pilots. Heart 96:668-72.
• Wailoo AJ, Tsuchiya A, McCabe C. (2009) Weighting must wait: incorporating equity concerns into cost effectiveness analysis may take longer than expected. Pharmacoeconomics 27(12):983-9.
• Wailoo AJ, Sutton A, Morgan A. (2009) The risk of febrile neutropenia in patients with non small cell lung cancer treated with docetaxel: a systematic review and meta-analysis. British Journal of Cancer 100(3):436-41.
• Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon R, Wolfe F. (2008) Biologic drugs for rheumatoid arthritis in the Medicare program: a cost effectiveness analysis. Arthritis and Rheumatism 58(4):939-46.
• Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KA, Brennan A, Nicholson KG. (2008) Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value in Health 11(2):160-71.
• Wailoo A, Anand P. (2005) The nature of procedural preferences for health-care rationing decisions. Social Science and Medicine 60(2): 223-36.